Posts

Garijo’s Plan to Revamp Sanofi: R&D Cleanup, More M&A, and a China Push Explained

on

Samsung Biologics Expands into Peptide API Manufacturing with $1.8B PolyPeptide Acquisition

on

Lilly Was Already Pharma’s Biggest Company. Now It’s Doing Deals to Match

on

Ipsen signals more deals to continue buying spree

on

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

on

Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues

on

Merck KGaA Axes SpringWorks Pipeline Assets Amid Pipeline Clear-Out While Pursuing M&A for External Innovation

on

GLP-1 Patent Cliffs and Biotech M&A Surge in 2026

on

Bayer Returns to Pharma M&A with Up to $2.45B Acquisition of Perfuse Therapeutics

on

Biogen Pursues Early-Stage Assets to Build Next Generation Growth Pipeline

on

From Debt to Acceptable Prices: Roche CEO Lists 3 Reasons for Sitting Out Big Pharma M&A Spree

on

Post-Hoc Live: Biopharma M&A Surge Signals Industry Revival

on

Gilead Scales Back M&A After $14.77B Spree but Open to Compelling Deals

on

Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts

on

Revolution Medicines Rejects Merck's Acquisition Bid, Stands Firm on Valuation Amid Ongoing Interest

on

JPM26 Day 1 Live Blog: Slow Deal Flow Amid Optimism at J.P. Morgan Healthcare Conference

on

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

on

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

on

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

on

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

on